TLDR
- First quarter adjusted earnings per share reached $0.75, surpassing the consensus estimate of $0.72
- Quarterly revenue totaled $13.8 billion, powered by robust Eliquis performance
- Net profit decreased 9% compared to the prior year at $2.7 billion; diluted earnings per share declined 10%
- Company maintains 2026 full-year projections: adjusted EPS of $2.80–$3.00 and revenue between $59.5B–$62.5B
- Shares of PFE advanced roughly 0.5% in early premarket activity to about $26.33
Pfizer launched 2026 on a positive note with first quarter results that exceeded expectations, pushing shares higher by approximately 0.5% to $26.33 during premarket hours.
The pharmaceutical company delivered adjusted earnings of $0.75 for each share, topping the Street’s consensus forecast of $0.72. Quarterly revenue reached $13.8 billion.
The company’s anticoagulant medication Eliquis, representing one of Pfizer’s most significant revenue streams, demonstrated continued strength. This product remains a critical performer as legacy medications show more resilience than market watchers anticipated.
Chief Financial Officer David Denton highlighted operational revenue expansion of 22% stemming from newly introduced and recently acquired therapies. This metric represents a trend Pfizer aims to sustain and expand.
Profitability metrics, on the other hand, showed some softness. The pharmaceutical giant recorded net income of $2.7 billion, representing a 9% year-over-year decrease. Diluted earnings per share settled at $0.47, marking a 10% annual contraction.
Company Maintains Full-Year Projections
Pfizer kept its 2026 financial outlook unchanged, standing by projections originally provided in December. Management continues to anticipate adjusted earnings per share in the $2.80 to $3.00 range alongside total revenue of $59.5 billion to $62.5 billion.
Wall Street analysts had been forecasting earnings of $2.96 per share and revenue of $61.4 billion, placing both squarely within the company’s guided parameters.
The pharmaceutical firm also reiterated that share repurchases are not anticipated during 2026. This projection remains firm irrespective of business performance throughout the year.
Chief Executive Albert Bourla adopted an optimistic stance. “We’ve launched 2026 with significant momentum,” he noted, highlighting favorable Phase 3 trial outcomes and promising intermediate-stage data.
Bourla emphasized oncology and weight management as two therapeutic areas where Pfizer believes it has “strong competitive positioning to emerge as a leader.”
Upcoming Patent Expirations Remain a Concern
The looming patent cliff continues to represent one of Pfizer’s most substantial near-term headwinds. Critical intellectual property protections covering blockbuster medications, including Eliquis, are scheduled to lapse prior to 2030.
Pfizer has implemented strategies to mitigate this impact. The organization has negotiated arrangements with generic drug producers to extend exclusivity periods on select therapies, including Vyndaqel.
Additionally, the company has been expanding its product portfolio through strategic acquisitions and internal development initiatives to strengthen the pipeline.
The research and development portfolio is reportedly progressing across numerous fronts, with oncology and obesity-related programs receiving special emphasis from executive leadership.
First quarter revenue expanded 5% year-over-year to $14.5 billion on a reported basis, exceeding market projections entering the earnings announcement.
The combination of earnings and revenue outperformance delivered a more favorable quarterly report than most investors had anticipated.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
